On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to charges that resulted from a deal to co-develop three after-cancer treatments with a Japanese drugmaker Daiichi Sankyo. But, Merck’s patent for Keytruda is expiring in 2028 so it needs more products under its belt. Like its peers, Moderna
Related Keywords
Japan , Germany , Japanese , Mainz Biomed , Daiichi Sankyo , Pfizer Inc , Merck Co Inc , Moderna Inc , European Oncology Lab , European Oncology , Stock Market Game , Benzinga Pro , Day Trial , Colorectal Cancer Screening , Cancer Vaccine , Lung Cancer , Ainz , Keytruda , Skin Cancer ,
vimarsana.com © 2020. All Rights Reserved.